PubRank

Michael F Good

Author PubWeight™ 89.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002 3.21
2 Malaria vaccine developments. Lancet 2004 1.77
3 A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol 2007 1.67
4 Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria. J Immunol 2010 1.65
5 Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. J Immunol 2005 1.56
6 Immunity to asexual blood stage malaria and vaccine approaches. Immunol Cell Biol 2002 1.51
7 The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection. J Exp Med 2002 1.48
8 Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003 1.26
9 Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect Immun 2005 1.25
10 Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria. J Immunol 2002 1.19
11 What really happens to dendritic cells during malaria? Nat Rev Microbiol 2008 1.14
12 Plasmodium strain determines dendritic cell function essential for survival from malaria. PLoS Pathog 2007 1.12
13 M protein typing of Thai group A streptococcal isolates by PCR-Restriction fragment length polymorphism analysis. BMC Microbiol 2005 1.10
14 Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum Vaccin 2010 1.09
15 High diversity of group A Streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. Clin Infect Dis 2004 1.08
16 Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination. Infect Immun 2003 1.07
17 emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009 1.06
18 Prospective surveillance of streptococcal sore throat in a tropical country. Pediatr Infect Dis J 2009 1.06
19 Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J Clin Invest 2010 1.05
20 Prospective surveillance of invasive group a streptococcal disease, Fiji, 2005-2007. Emerg Infect Dis 2009 1.01
21 The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc Natl Acad Sci U S A 2003 1.01
22 A case for whole-parasite malaria vaccines. Int J Parasitol 2007 0.99
23 Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006 0.98
24 Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice. Proc Natl Acad Sci U S A 2011 0.98
25 Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help. J Immunol 2013 0.98
26 Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One 2009 0.97
27 Systemic tumor necrosis factor generated during lethal Plasmodium infections impairs dendritic cell function. J Immunol 2007 0.95
28 Interactions between malaria parasites and the host immune system. Curr Opin Immunol 2005 0.95
29 Induction of autoimmune valvulitis in Lewis rats following immunization with peptides from the conserved region of group A streptococcal M protein. J Autoimmun 2003 0.94
30 M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol 2005 0.94
31 Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem 2007 0.94
32 Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew Chem Int Ed Engl 2010 0.94
33 Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. J Exp Med 2013 0.94
34 Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis 2005 0.93
35 What have we learnt from mouse models for the study of malaria? Eur J Immunol 2009 0.92
36 Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. Bioorg Med Chem 2008 0.92
37 CD8+ T lymphocyte-mediated loss of marginal metallophilic macrophages following infection with Plasmodium chabaudi chabaudi AS. J Immunol 2006 0.92
38 Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1. Infect Immun 2002 0.91
39 Low-level Plasmodium falciparum blood-stage infection causes dendritic cell apoptosis and dysfunction in healthy volunteers. J Infect Dis 2012 0.89
40 Escaping the immune system: How the malaria parasite makes vaccine development a challenge. Trends Parasitol 2013 0.89
41 Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. J Infect Dis 2006 0.89
42 Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Hum Vaccin Immunother 2012 0.88
43 Cross-species malaria immunity induced by chemically attenuated parasites. J Clin Invest 2013 0.88
44 Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 2002 0.88
45 A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun 2002 0.87
46 Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship. PLoS One 2012 0.87
47 Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine. Infect Immun 2008 0.86
48 Analysis of circumsporozoite protein-specific immune responses following recent infection with Plasmodium vivax. Am J Trop Med Hyg 2004 0.86
49 Malaria vaccines: the case for a whole-organism approach. Expert Opin Biol Ther 2008 0.85
50 Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 2003 0.85
51 Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci 2003 0.85
52 A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 2011 0.85
53 Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol Res 2006 0.84
54 Vaccination against rheumatic heart disease: a review of current research strategies and challenges. Curr Infect Dis Rep 2012 0.84
55 Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge. Vaccine 2002 0.84
56 Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. J Med Chem 2010 0.83
57 Immune response to superoxide dismutase in group A streptococcal infection. FEMS Immunol Med Microbiol 2004 0.83
58 Antibody reactivity to linear epitopes of Plasmodium falciparum cytoadherence-linked asexual gene 9 in asymptomatic children and adults from papua new Guinea. Am J Trop Med Hyg 2005 0.82
59 Inhibition of 19-kDa C-terminal region of merozoite surface protein-1-specific antibody responses in neonatal pups by maternally derived 19-kDa C-terminal region of merozoite surface protein-1-specific antibodies but not whole parasite-specific antibodies. J Immunol 2004 0.82
60 Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. Vaccine 2007 0.82
61 Dendritic cell biology during malaria. Cell Microbiol 2007 0.82
62 Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain. Clin Vaccine Immunol 2009 0.81
63 Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol 2002 0.81
64 Characterization of the antibody response against Plasmodium falciparum erythrocyte membrane protein 1 in human volunteers. Infect Immun 2007 0.80
65 Polyspecific malaria antibodies present at the time of infection inhibit the development of immunity to malaria but antibodies specific for the malaria merozoite surface protein, MSP1, facilitate immunity. Parasite Immunol 2002 0.80
66 Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine. Nanomedicine (Lond) 2013 0.80
67 Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem 2006 0.80
68 The role of the 19-kDa region of merozoite surface protein 1 and whole-parasite-specific maternal antibodies in directing neonatal pups' responses to rodent malaria infection. J Immunol 2003 0.80
69 Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines. J Med Chem 2008 0.79
70 Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malar J 2009 0.79
71 Identification of early cellular immune factors regulating growth of malaria parasites in humans. Immunity 2005 0.78
72 M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus. Curr Drug Deliv 2013 0.78
73 Experimental asexual blood stage malaria immunity. Curr Protoc Immunol 2011 0.78
74 Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. Nanomedicine 2010 0.78
75 Soluble CD38 significantly prolongs the lifespan of memory B-cell responses. Immunology 2008 0.78
76 Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis 2006 0.78
77 Nanovaccines and their mode of action. Methods 2013 0.78
78 Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation. J Org Chem 2006 0.78
79 Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 2004 0.78
80 Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes. J Med Chem 2012 0.77
81 Cell trafficking. Malaria blood-stage parasite-specific CD4+ T cells after adoptive transfer into mice. Methods Mol Med 2002 0.77
82 Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus. Biopolymers 2008 0.77
83 Mixed results for a malaria vaccine. Nat Med 2011 0.77
84 Immunology. Platelets kill the parasite within. Science 2012 0.77
85 Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct. Indian J Med Res 2004 0.77
86 Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines. Bioconjug Chem 2014 0.76
87 Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity. Nanomedicine (Lond) 2014 0.76
88 Polyacrylate-based delivery system for self-adjuvanting anticancer peptide vaccine. J Med Chem 2014 0.76
89 An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system. Nanomedicine 2013 0.76
90 Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model. Clin Vaccine Immunol 2011 0.76
91 In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci. Clin Vaccine Immunol 2012 0.75
92 Malaria's journey through the lymph node. Nat Med 2007 0.75
93 Disarming the malaria parasite. Nat Med 2008 0.75
94 Malaria parasites up close. Nat Med 2006 0.75
95 Malaria vaccine research: lessons from 2008/9. Future Microbiol 2009 0.75
96 Vaccine delivery utilizing liposaccharides. Adv Exp Med Biol 2009 0.75
97 Historical review: Sir Gustav Nossal--immunologist and more. Trends Immunol 2004 0.75
98 Back to the future for antiparasite vaccines? Expert Rev Vaccines 2013 0.75
99 A novel pathway of haematopoiesis revealed after experimental malaria infection. Immunol Cell Biol 2010 0.75
100 Vaccine delivery: synthesis and investigation of a highly pure, multi-epitopic lipopeptide vaccine candidate. Adv Exp Med Biol 2009 0.75
101 A case of 'hit-and-run' in Plasmodium genetics. Trends Parasitol 2006 0.75
102 Induction of anti-Plasmodium immunity following subpatent infection with live erythrocytic stages and drug cure. Methods Mol Biol 2013 0.75
103 The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus. Med Chem 2016 0.75
104 Method for the synthesis of highly pure vaccines using the lipid core peptide system. J Pept Sci 2006 0.75